Share price · MRNA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MRNA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Aug 2026+177.0%
- 10 Jul 2026-10.8%
Nothing announced by MRNA that day or the session before.
- 26 Jun 2026+12.6%
- 22 Jun 2026-7.2%
Nothing announced by MRNA that day or the session before.
- 17 Jun 2026+11.6%
Nothing announced by MRNA that day or the session before.
- 16 Jun 2026+6.3%
Nothing announced by MRNA that day or the session before.
- 5 Jun 2026-8.0%
Nothing announced by MRNA that day or the session before.
- 3 Jun 2026+7.5%
Nothing announced by MRNA that day or the session before.
- 8 May 2026+12.0%
Nothing announced by MRNA that day or the session before.
- 4 Mar 2026+16.0%
Nothing announced by MRNA that day or the session before.
Share of unusual movement by asset
For each asset, the share of MRNA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
elasomeran(Spikevax) | Approved | SARS-CoV-2 spike proteinVaccine | COVID-19 |
| Approved | RSV pre-F proteinVaccine | Respiratory Syncytial Virus Infection | |
| Phase 3 | Patient-specific tumor neoantigens (personalized, up to 34 per patient)Vaccine | Non-Small Cell Lung CancerMelanoma | |
| Phase 1/2 | BCMA, GPRC5D, FcRH5RNA / oligonucleotide | Multiple Myeloma |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
April 2027 (1)
What to watch
2028 (2)
2029 (2)
2030 (2)
2031 (1)
September 2031 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
2033 (1)
May 2033 (1)
What to watch
2034 (1)
August 2034 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.3B | $583M | $1.2B+ $4.0B short-term inv. | —-$1.6B operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $145M | $651M | $1.7B+ $3.4B short-term inv. | $782M-$526M operating cash flow | report ↗ |
| 2026-Q1 | $389M | $649M | $1.9B+ $3.3B short-term inv. | $1.3B-$630M operating cash flow | report ↗ |
| 2025-Q3 | $1.0B | $801M | $1.1B+ $3.4B short-term inv. | $200M-$847M operating cash flow | report ↗ |
| 2025-Q2 | $142M | $700M | $1.3B+ $3.9B short-term inv. | $825M-$919M operating cash flow | report ↗ |
| 2025-Q1 | $108M | $856M | $1.6B+ $4.4B short-term inv. | $971M-$1.0B operating cash flow | report ↗ |
| 2024-Q3 | $1.9B | $1.1B | $1.6B+ $5.2B short-term inv. | —-$1.6B operating cash flow | report ↗ |
| 2024-Q2 | $241M | $1.2B | $2.5B+ $6.0B short-term inv. | $1.3B-$1.3B operating cash flow | report ↗ |
| 2024-Q1 | $167M | $1.1B | $2.1B+ $6.5B short-term inv. | $1.2B-$989M operating cash flow | report ↗ |
| 2023-Q3 | $1.8B | $1.2B | $3.0B+ $4.6B short-term inv. | $3.6B-$1.6B operating cash flow | report ↗ |
| 2023-Q2 | $344M | $1.1B | $3.8B+ $4.7B short-term inv. | $1.4B-$915M operating cash flow | report ↗ |
| 2023-Q1 | $1.9B | $1.1B | $3.5B+ $5.5B short-term inv. | —-$1.2B operating cash flow | report ↗ |
| 2022-Q3 | $3.4B | $820M | $3.0B+ $5.3B short-term inv. | —$252M operating cash flow | report ↗ |
| 2022-Q2 | — | $710M | $2.9B+ $5.0B short-term inv. | —$304M operating cash flow | report ↗ |
| 2022-Q1 | — | $554M | $5.1B+ $5.1B short-term inv. | —$2.8B operating cash flow | report ↗ |
| 2021-Q3 | — | $521M | $5.6B+ $3.4B short-term inv. | —$3.3B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.9B | $3.1B | $2.6B+ $3.2B short-term inv. | $706M-$1.9B operating cash flow | report ↗ |
Moderna reported fiscal-year 2025 revenue of $1,944M, down 39.9% YoY from $3,236M, with R&D spend of $3,132M, down 31.1% YoY. The company reported a net loss of $2,822M for the year, cash and equivalents of $2,597M, and a full-year GAAP diluted EPS of $(7.26); fourth-quarter revenue was $678M with a net loss of $(826)M and GAAP EPS of $(2.11).
For 2026, Moderna reiterated plans for up to 10% revenue growth and GAAP operating expense reductions, with R&D projected at approximately $3.0B, cost of sales about $0.9B, and year-end cash and investments of $5.5B to $6.0B. Pipeline updates included regulatory review for its seasonal flu vaccine in the EU, Canada, and Australia, a U.S. FDA Refusal-to-File letter with a requested Type A meeting, full enrollment of the norovirus Phase 3 trial with a 2026 readout expected, and full enrollment of the Phase 2 intismeran autogene trial in muscle invasive bladder cancer.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $3.2B | $4.5B | $1.9B+ $5.1B short-term inv. | $890M-$3.0B operating cash flow | report ↗ |
| 2023-FY | $6.8B | $4.8B | $2.9B+ $5.7B short-term inv. | $1.2B-$3.1B operating cash flow | report ↗ |
| 2022-FY | $19.3B | $3.3B | $3.2B+ $6.7B short-term inv. | —$5.0B operating cash flow | report ↗ |
| 2021-FY | $18.5B | $2.0B | $6.9B+ $3.9B short-term inv. | —$13.6B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 26 sales ($98.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Hoge Stephen · President | Option exercise | 76,452 | $12.21 | $933K | Form 4 |
| 2026-11-17 | Hoge Stephen · President | Open-market sale | 33,976 | $211.45 | $7.2M | Form 4 |
| 2026-11-17 | Hoge Stephen · President | Open-market sale | 5,082 | $212.57 | $1.1M | Form 4 |
| 2026-11-17 | Hoge Stephen · President | Open-market sale | 157 | $214.19 | $34K | Form 4 |
| 2026-11-17 | Hoge Stephen · President | Option exercise (derivative) | 76,452 | — | — | Form 4 |
| 2026-11-16 | Hoge Stephen · President | Option exercise | 76,453 | $12.21 | $933K | Form 4 |
| 2026-11-16 | Hoge Stephen · President | Open-market sale | 39,160 | $219.66 | $8.6M | Form 4 |
| 2026-11-16 | Hoge Stephen · President | Gift | 400,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 716 reporting institutions held 308.2M shares ($15.5B, 76.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 45,672,024 | $2.3B |
| 2 | BlackRock, Inc. | 29,635,876 | $1.5B |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 22,872,458 | $1.2B |
| 4 | BAILLIE GIFFORD & CO | 19,985,876 | $1.0B |
| 5 | Capital World Investors | 18,697,694 | $949.8M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 15,616,367 | $793.3M |
| 7 | STATE STREET CORP | 14,861,409 | $755.0M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 9,435,132 | $478.5M |
| 9 | TWO SIGMA INVESTMENTS, LP | 9,086,404 | $461.6M |
| 10 | MORGAN STANLEY | 8,471,263 | $430.3M |
| 11 | Theleme Partners LLP | 8,048,245 | $408.9M |
| 12 | GOLDMAN SACHS GROUP INC | 6,603,697 | $335.5M |
| 13 | Invesco Ltd. | 4,784,758 | $243.1M |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4,734,356 | $240.5M |
| 15 | Flagship Pioneering, LLC | 4,632,149 | $235.3M |